梅州治疗白带异常去哪家医院较好(梅州治疗宫颈糜烂2度多少钱) (今日更新中)

BEIJING, Aug. 25 (Xinhua) -- China pledged on Thursday to make more efforts to aid people living in the drought-stricken Horn of Africa in collaboration with the International Committee for the Red Cross (ICRC)."We noticed that the ICRC launched an appeal regarding the situation in the Horn of Africa. The Red Cross Society of China (RCSC) has decided to donate 4 million yuan (about 623,000 U.S. dollars) to the ICRC for its humanitarian aid in the region," said Hua Jianmin, president of the RCSC, while meeting with visiting ICRC President Jakob Kellenberger in Beijing on Thursday.Earlier this month, the RCSC donated 8 million yuan (1.25 million dollars) to famine-plagued countries in the Horn of Africa to be used for emergency humanitarian aid.A donation of 2 million yuan was sent to Kenya through the country's Red Cross organization, while another 2 million went to Ethiopia. The other 4 million yuan was donated to other countries in the region.The Chinese government has decided to provide a total of 90 million yuan (14 million dollars) in emergency food assistance to countries in the Horn of Africa."The Red Cross Society of China is willing to work together with the International Committee for the Red Cross to meet the needs of those who have been affected (by the droughts)," Hua said.Some 12.4 million people in Kenya, Ethiopia, Somalia and other countries in the region are in dire need of food due to a serious drought, the worst to hit the region since the 1980s.

RIO DE JANEIRO, July 28 (Xinhua) -- Brazilians are eating a lot of rice and beans as well as high-calorie junk food lacking nutrition, a study released Thursday by the Brazilian Institute of Geography and Statistics (IBGE) found.According to the study, over 90 percent of Brazilians eat daily helpings of fruits and vegetables lower than the levels recommended by the Health Ministry (400 grams). Also,the consumption of sugary drinks (juices, fruit drinks and soft drinks) is twice as high as recommended by the ministry.Rice and beans, along with coffee and juices, are the most popular in Brazilians' diet. Teenagers are the main consumers of those drinks, drinking twice as much as adults. Men eat less greens and fruits than women, but drink five times more alcohol.In urban areas, the consumption of beer, soft drinks, sandwiches, and salty bread is higher. Brazilians in rural areas have a healthier diet, richer in rice, beans, fish, cassava flour, and sweet potatoes.Along with a lack of physical activity, the Brazilians' poor diet was cited as one of the main causes of obesity in the country. According to a Health Ministry study published in April, 48 percent of Brazilians are overweight, and 15 percent are obese.

CANBERRA, June 6 (Xinhua) -- Australian beef is not to blame for a recent outbreak of E.coli in Japan, Meat and Livestock Australia confirmed on Monday.Twenty people have fallen ill in Japan's Toyama prefecture, with 15 of them infected with the O157 strain of E.coli after eating at a popular Korean-style barbecue restaurant chain, Gyukaka, on May 6.The operators of the restaurant chain, REINS International, said they suspected the bacterium might have been carried by beef imported from Australia.After conducting an investigation into the Japanese outbreak, regional manager for Meat and Livestock Australia, Melanie Brock, said testing shows Australian beef was not the source of the outbreak."The Toyama prefecture health authorities have confirmed following a thorough inspection that imported Australian beef was not the source of an incident of E.coli," Brock said in a statement on Monday."The authorities continue to investigate other food consumed by the affected customers."Brock said Australian beef has long been recognized by the Japanese trade and consumers for its strong safety record.Brock added that Australian beef for export to Japan is processed under the veterinary supervision of the Australian Quarantine and Inspection Service, and is recognized internationally as bearing a high hygienic standard.

PHNOM PENH, Aug. 17 (Xinhua) -- The critically endangered Irrawaddy dolphin population in the Mekong River numbers just 85, World Wildlife Fund (WWF) new research revealed on Wednesday.Calf survival was found to be very low, leading researchers to conclude that the small population is declining and at high risk of extinction, said the Fund's statement sent to Xinhua News Agency on Wednesday.According to Li Lifeng, Director of WWF's Freshwater Program, the research is based on photographic identification of dolphins through individually unique features of their dorsal fins. "Most of the dolphins can be identified, and we use that information to estimate the population size," he said.Although this population estimate is slightly higher than the previous estimate, the researchers were quick to note that the population had not increased over the last few years."With a larger dataset and recent analytical advances, previously unidentifiable dolphins which had few marks on their dorsal fins have been included," he added.However, surveys conducted from 2007 to 2010 show the population slowly declining."Evidence is strong that very few young animals survive to adulthood, as older dolphins die off and are not replaced," he explained."Pressures of gill net entanglement and high calf mortality we are really worried for the future of dolphins," Li said.However, Touch Seang Tana, chairman of Cambodia's Commission for Conversation and Development of the Mekong River Dolphins Eco- tourism Zone, rejected the WWF's finding, saying that last year, 4 dolphins were killed by fishing nets, but up to 7 newborn dolphin babies were found.He estimated that the total population of Mekong dolphins in the north-eastern provinces of Kratie and Stung Treng is between 155 and 177 now, up from just 100 in 2006.The Mekong River Irrawaddy dolphin has been listed as critically endangered on the World Conservation Union Red List of Threatened Species since 2004.

LOS ANGELES, June 5 (Xinhua) -- U.S. researchers have developed two new drugs that can prolong the lives of patients with advanced melanoma, it was announced on Sunday.Research on both drugs was presented at the on-going annual meeting of the American Society of Clinical Oncology in Chicago, according to HealthDay News.This is the first big news in years for treatment of melanoma, one of the deadliest forms of skin cancer and one that is notoriously difficult to treat, let alone cure, the report said.The first treatment, vemurafenib, inhibits a gene mutation harbored in half of all melanoma patients, but is not yet approved by the U.S. Food and Drug Administration.The other drug, Yervoy (ipilumumab), is an immune system therapy that won approval in March."The March FDA approval of ipilumumab (Yervoy) was the first new drug approval for melanoma in 13 years," said Tim Turnham, executive director of the Melanoma Research Foundation.The two drugs were developed by researchers at Memorial Sloan- Kettering Cancer Center in New York City, the report said."This is really a huge step toward personalized care in melanoma," Dr. Paul Chapman, lead author of the first study and the attending physician in the melanoma/sarcoma service at Memorial Sloan-Kettering, said in a statement. "This (vemurafenib) is the first successful melanoma treatment tailored to patients who carry a specific gene mutation in their tumor, and could eventually become one of only two drugs available that improves overall survival in advanced cancers.""Having two trials that show a benefit in survival in patients with melanoma, both of these in first-line settings -- we weren't here just a few years ago," said Dr. Stephen Hodi, director of the Melanoma Center at Dana Farber Cancer Institute in Boston. "These are huge, paradigm-shifting results for the field."In the vemurafenib trial, sponsored by the drug's makers, researchers randomly assigned 675 patients with advanced, inoperable melanoma to receive either the chemotherapy drug dacarbazine or vemurafenib. Vemurafenib targets the V600E mutation in the BRAF gene.At the three-month mark, patients taking vemurafenib were 63 percent less likely to die and 74 percent less likely to die or see their cancer return, compared to patients taking dacarbazine alone.Few patients had side effects in the vemurafenib group, although some did develop squamous cell carcinoma, a less dangerous form of skin cancer.This is the first drug that has been proven superior to chemotherapy in this group of hard-to-treat patients, the researchers said."There was such a substantial benefit that we recommended that patients cross over," Chapman said at a Sunday news briefing. "It' s unprecedented to report a trial this early. The median follow-up time was three months." Yet the differences between the two groups became evident almost immediately.Dr. Lynn Schuchter, co-moderator of the briefing and division chief of hematology-oncology at Abramson Cancer Center of the University of Pennsylvania in Philadelphia, said symptoms subsided in some patients almost immediately, enabling them to cut back on pain medication in just 72 hours."The median time to progression with dacarbazine was 1.6 months versus three months with vemurafenib, which is a huge difference," said Chapman.In the second study, about 500 patients were randomly picked to receive Yervoy plus dacarbazine or dacarbazine alone.Those taking both drugs lived a median of 11.2 months compared to 9.1 months for those taking dacarbazine alone. Time to recurrence of disease was about the same for both groups: 2.8 months and 2.6 months, respectively.Almost half of those taking the combination therapy were alive after one year, compared to 36.3 percent in the other group. After two years, the rates were 28.5 percent and 17.9 percent, respectively.By three years out, 20.8 percent of those in the combination group were alive compared with 12.2 percent of those taking chemotherapy alone.This is the first study to combine chemotherapy and immunotherapy both safely and effectively.A study to test vemurafenib in combination with Yervoy has already begun, according to HealthDay News.

来源：资阳报